Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943237 | 0.90 | TDO2 (0.48) | PAICSMMP1TDO2FPR2PROKR1 | |
| Hydrochloric Acid SCHEMBL2779881 | 0.89 | TDO2 (0.47) | PAICSMMP1TDO2FPR2PROKR1 | |
| Hydrochloric Acid SCHEMBL942643 | 0.89 | TDO2 (0.47) | PAICSMMP1TDO2FPR2PROKR1 | |
| SCHEMBL13560051 | 0.81 | HTR2C (0.48) | — | |
| SCHEMBL4823398 | 0.81 | HTR2C (0.48) | — | |
| SCHEMBL14127773 | 0.79 | MAPT (0.49) | PAICSTDO2DGAT1KCNH2TMEM97 | |
| SCHEMBL30843204 | 0.79 | FPR2 (0.49) | MMP1TDO2FPR2PROKR1IP6K1 | |
| Acetic Acid SCHEMBL4325103 | 0.78 | HRH1 (0.49) | IP6K1TMEM97SIGMAR1HRH1 | |
| SCHEMBL5418879 | 0.77 | HRH3 (0.48) | MMP1TDO2FPR2PROKR1KCNH2 | |
| SCHEMBL5318377 | 0.77 | MMP1 (0.52) | MMP1FPR2PROKR1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-2064202-A2 | A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | PTMS, NT5C, CDK5 | PAICS 222/4885MMP1 1919/4885TDO2 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.